Stryker, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a $448.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors including Stryker’s strong financial performance in the third quarter of 2025. The company exceeded expectations in both revenue and earnings per share, prompting an upward revision in its organic revenue and EPS guidance for the year. Despite an anticipated increase in tariff impacts, Stryker remains confident in its ability to fully offset these costs.
Additionally, the company demonstrated robust performance across its various business segments, supported by high procedure volumes, the introduction of new products, and a backlog in capital equipment. Although there was a slight deceleration in organic sales growth, the company faced challenging comparisons from the previous quarter. Improvements in gross and operating margins further underscore Stryker’s effective execution and strategic initiatives, justifying the Buy rating.
Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific, TransMedics Group, and Penumbra. According to TipRanks, Matson has an average return of -2.5% and a 39.96% success rate on recommended stocks.
In another report released today, Barclays also maintained a Buy rating on the stock with a $453.00 price target.